Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Retained Earnings (2016 - 2026)

Oramed Pharmaceuticals filings provide 15 years of Retained Earnings readings, the most recent being -$123.4 million for Q4 2025.

  • Quarterly Retained Earnings rose 30.11% to -$123.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$123.4 million through Dec 2025, up 30.11% year-over-year, with the annual reading at -$123.4 million for FY2025, 30.11% up from the prior year.
  • Retained Earnings hit -$123.4 million in Q4 2025 for Oramed Pharmaceuticals, down from -$122.6 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$102.8 million in Q1 2021 and bottomed at -$184.3 million in Q1 2025.
  • Average Retained Earnings over 5 years is -$148.0 million, with a median of -$155.3 million recorded in 2022.
  • The largest annual shift saw Retained Earnings fell 25.01% in 2021 before it surged 30.11% in 2025.
  • Oramed Pharmaceuticals' Retained Earnings stood at -$122.7 million in 2021, then crashed by 32.86% to -$163.1 million in 2022, then rose by 3.39% to -$157.6 million in 2023, then fell by 12.1% to -$176.6 million in 2024, then skyrocketed by 30.11% to -$123.4 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Retained Earnings are -$123.4 million (Q4 2025), -$122.6 million (Q3 2025), and -$171.0 million (Q2 2025).